X4 Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022

BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today announced that it will present a poster on its Waldenström’s macroglobulinemia program at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022 to be held in New Orleans, LA April 8-12, 2022.

Presentation Details:

Poster Title: Mavorixafor Enhances Efficacy of Bruton’s Tyrosine Kinase Inhibitors by Overcoming the Protective Effect of Bone Marrow Stroma on Tumor Cells in Waldenström’s Macroglobulinemia
Presenter: Chi Nguyen Ph.D., Group Leader, Discovery at X4 Pharmaceuticals
Poster #: 6093   
Poster Session: Drug Targeting and Treatment Response of the Microenvironment
Session Date/Time: Sunday April 10, 1:30-5 pm CT

A copy of the poster will be available on X4’s corporate website at the conclusion of the conference.